Phase 2 Chronic Kidney Disease Trial, Recruiting NCT07304817 Sponsor: University Medical Center Groningen Condition: Chronic Kidney Disease
Back to Chronic Kidney Disease

Phase 2 Chronic Kidney Disease Trial, Recruiting

NCT07304817
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older, of any gender, who have signed and dated a consent form before entering the trial
  • People with heart failure (regardless of how well the heart is pumping) and a certain level of kidney function, as measured by a blood test called eGFR, falling between 25 and 90
  • People with established heart or blood vessel disease and an eGFR between 25 and 60
  • People with established heart or blood vessel disease AND type 2 diabetes and an eGFR between 25 and 90
  • People whose blood potassium level is at or below 5.0 mmol
  • People who are currently on a medication called Empagliflozin, or whose treating doctor considers them eligible for treatment with it
  • People who have not used a specific type of heart/blood pressure medication called an MRA or aldosterone synthase inhibitor in the 6 months before joining
  • People who have been on stable doses of other recommended heart or kidney medications for at least 4 weeks before joining
  • People who are being managed as outpatients (not currently admitted to hospital)

Who may not be able to join:

  • People who are unable to understand or sign a consent form
  • People who have a strong medical reason why they cannot take a type of medication called an aldosterone antagonist
  • People who have a strong medical reason why they cannot take a type of medication called an SGLT2 inhibitor
  • People who have been hospitalised for heart failure, or had a heart attack, heart surgery, stroke, or mini-stroke in the 90 days before joining
  • Women who are pregnant, breastfeeding, or planning to become pregnant during the study period

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
12 May 2026
Est. completion
1 February 2028

Where this trial is recruiting

🇳🇱 Netherlands

Primary endpoints

Kidney function (eGFR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov